Omeros (OMER) Projected to Post Earnings on Tuesday

Omeros (NASDAQ:OMER) is expected to be posting its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect Omeros to post earnings of ($0.57) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Omeros Stock Up 4.3%

Shares of OMER stock opened at $12.05 on Friday. Omeros has a 12 month low of $2.95 and a 12 month high of $17.65. The firm has a market cap of $854.35 million, a PE ratio of -5.97 and a beta of 2.44. The stock has a 50 day moving average of $12.63 and a 200-day moving average of $8.68.

Analyst Upgrades and Downgrades

OMER has been the subject of several research analyst reports. D. Boral Capital reiterated a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Tuesday, January 27th. HC Wainwright boosted their price objective on shares of Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Omeros has an average rating of “Moderate Buy” and a consensus target price of $40.33.

Insider Activity

In other news, CAO David J. Borges sold 30,000 shares of Omeros stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total transaction of $369,300.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 12.90% of the company’s stock.

Institutional Investors Weigh In On Omeros

Several large investors have recently made changes to their positions in the company. Invesco Ltd. raised its stake in shares of Omeros by 26.8% in the fourth quarter. Invesco Ltd. now owns 154,782 shares of the biopharmaceutical company’s stock worth $2,658,000 after acquiring an additional 32,707 shares during the last quarter. Corient Private Wealth LLC increased its holdings in shares of Omeros by 12.9% in the fourth quarter. Corient Private Wealth LLC now owns 687,325 shares of the biopharmaceutical company’s stock valued at $11,805,000 after purchasing an additional 78,563 shares in the last quarter. Virtus Investment Advisers LLC acquired a new stake in shares of Omeros in the fourth quarter valued at approximately $450,000. Wellington Management Group LLP raised its position in Omeros by 4.2% in the 4th quarter. Wellington Management Group LLP now owns 202,617 shares of the biopharmaceutical company’s stock worth $3,480,000 after purchasing an additional 8,170 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in Omeros by 10.0% during the 4th quarter. Millennium Management LLC now owns 441,811 shares of the biopharmaceutical company’s stock worth $7,588,000 after buying an additional 39,997 shares in the last quarter. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.